Related Experiment Videos
Intravenous salbutamol in the treatment of status asthmaticus in children
Insights
Continuous intravenous salbutamol effectively managed status asthmaticus in children, reducing carbon dioxide levels and avoiding mechanical ventilation in most cases. This bronchodilator proved safe and effective for severe pediatric asthma attacks.
Area of Science:
- Pediatric Pulmonology
- Critical Care Medicine
- Pharmacology
Background:
- Status asthmaticus is a severe asthma exacerbation unresponsive to standard treatments.
- Mechanical ventilation is often required for pediatric patients with respiratory failure due to severe asthma.
Purpose of the Study:
- To evaluate the efficacy and safety of continuous intravenous salbutamol infusion for managing status asthmaticus in children.
- To compare salbutamol's effectiveness with intravenous isoproterenol in pediatric patients.
Main Methods:
- A study involving 14 children (16 episodes) with respiratory failure from status asthmaticus.
- Administered a loading dose of salbutamol followed by a continuous infusion, with dose adjustments based on response.
- Monitored PaCO2 levels and heart rate throughout the treatment period.
Main Results:
- Sustained reduction in PaCO2 was achieved in 69% of episodes within 4 hours.
- Mechanical ventilation was necessary in 11% of cases due to persistent CO2 retention.
- Intravenous salbutamol showed a less significant impact on heart rate compared to isoproterenol and reduced bronchospasm recurrence.
Conclusions:
- Continuous intravenous salbutamol is a safe and effective bronchodilator for severe pediatric status asthmaticus.
- Salbutamol may be preferable to isoproterenol due to its beta 2-receptor specificity and improved outcomes.
- This treatment can potentially prevent the need for mechanical ventilation in pediatric asthma emergencies.
Abstract:
The management of status asthmaticus using a continuous iv infusion of salbutamol was studied in 14 children with a total of 16 episodes of respiratory failure, unresponsive to conventional bronchodilator therapy. The mean PaCO2 at the start of the infusion was 60 +/- 6 torr. A loading dose of 1 microgram/kg X min body weight was given over 10 min, followed by an infusion of 0.2 microgram/kg X min which was increased in 0.1-microgram/kg steps according to response. The maximum dose was 4 microgram/kg X min. On 11 (69%) occasions a sustained reduction in PaCO2 was achieved within 4 h of starting the infusion. In 5 (11%) instances no reduction in PaCO2 was seen and mechanical ventilation was instituted because of increasing respiratory distress and CO2 retention. Mean heart rate during the infusion increased from 161 to 183 beat/min. Comparison with previous data from 30 pediatric patients (40 infusions) receiving iv isoproterenol showed less effect on heart rate and a more sustained fall in PaCO2 without the recurrence of bronchospasm. We found salbutamol to be a safe and effective bronchodilator capable of reversing severe bronchospasm in most children who would otherwise require mechanical ventilation. Its greater specificity for beta 2-receptors may make it preferable to isoproterenol.